This startup venture anticipates demonstrating potent molecules to halt Alzheimer's and dementia that occurs in old age.
Click for overview
Executive Summary Metavo Life Science, Inc. Acrobat pdf file
Metavo Investment Summary Memorandum .pdf file
Aging-Alzheimer's Disease Discussion MS Powerpoint file
Nutrients make a difference to the Aging-Rejuvenation processes.!
| UTTx, inc. has
formed a limited partnership, METAVO LLC. in partnership with Genesys
Ventures, inc. [Winnipeg, MB, Canada]
to develop and commercialize an innovative, disruptive technology to
reduce the 50% statistical risk
of losing your minds after 80 years of age. It has always been normal to expect to have reduced physical capabilities as we pass through the years. Most Americans expect that an extended longevity will be a reality during their lifetime. The expectation is that we all can live to, and past, 100 years old, in good health and having an independent living status. No-one hopes to have to rely upon their relatives, or the government, for assistance in any period of their lives. However, the stats show that about 50% of all Americans will lose their minds to a neuropathologic disease and/or dementia as they age past 80. The data shows that Alzheimer's disease symptoms will afflict one half of all living individuals at this time of life. Don't believe it ? They are real, disturbing, and, of course, not published much. What will an extended life mean to you if you don't have a functioning mind ?? Not much I will bet, we have all seen the wonderful life of the animals, especially primates, in a Zoo. |
University Technologies of Texas, Inc. Web Home Page
| UTTx, inc. develops and
commercializes innovative research and disruptive technologies to
create competitive advantage for startup companies and businesses
seeking new product directions. New technologies provide a distinct
strategic advantage to the business through valuable assets and
intellectual property portfolios. We provide our customers with new,
innovative, better products that will lead to improved profitability.
Our technologies expand the possibilities beyond prevailing boundaries.
We strive to operate at three distinct levels: first to act as a source
of disruptive technologies and seek to discover potential licensing
candidates for the technology; second to act as consultants to find,
develop and refine technologies for requesting clients, and thirdly to
develop disruptive technologies and those with extraordinary potential
into startup businesses. New exciting technologies are available from a
wide variety of sources including universities, federal laboratories,
other government facilities and individual inventors. Generally these
sources develop technologies only to the crude prototype stage which to
become market ready require further extensive development. This process
requires time, money and effort; commodities that are often lacking or
in short supply. In particular universities and federal laboratories
conduct basic research and it is not an integral part of their strategy
or process to develop innovations beyond the prototype stage. UTTx has
defined its mission and operational strategy to select the most
promising technologies and bring them to a marketable stage and either
license the intellectual property to an interested corporation in the
appropriate marketplace or to actually create a demand for the product
or service through the formation and development of a startup company. |
Click for over view
| Successful commercialization of
health technology requires quality innovation plus experienced
management, market and technical expertise, and access to sufficient
capital. These elements represent the gap between innovation &
commercialization …without them the potential is never realized.
Genesys Venture Inc. (GVI) provides the expertise, experience and
energy required to start-up and manage emerging health and
biotechnology ventures. Founded by renowned bio-entrepreneur Dr. Albert
D. Friesen, the GVI team has extensive experience in technology and
business development to offer its clients.
The Company provides many services to client companies through an
enhanced incubation model and active participation. GVI takes the idea
of an incubator to the next level, becoming actively involved with each
new venture and offering a tailored mix of services vital to
successfully develop a technology to address market opportunities.
GVI believes that entrepreneurs on the leading edge of new and
innovative technologies can benefit from a location that complies with
all the high standards needed for the industry. To that end, GVI is
situated in a newly constructed facility that houses both research and
management staff of GVI and several client companies. The custom
designed building provides access to business structure and state of
the art equipment. In addition, GVI is capable of providing incubation
to companies located wherever their R&D needs are suited.
A proven track record and an experienced and talented team make Genesys
Venture Inc. a unique vehicle for developing innovative ventures. GVI’s
established reputation and strong relationships within the life science
and financial community assist in identifying strategic partners and
building value through the product development process...this approach
has resulted in zero failures.
GVI is co-owned by the Manitoba Science & Technology Fund, a
venture capital fund dedicated to growth of this sector within
Manitoba. GVI and its clients also benefit from a strong relationship
with the University of Manitoba and all three levels of government.
GVI has a referral and cooperation agreement with CentreStone Ventures
Fund. CentreStone Ventures is a life sciences focused private venture
capital fund investing primarily in early stage therapeutics, medical
device, diagnostic and drug delivery companies. |
){kind=link}